Bilberry — Frequently Asked Questions

The WWII British pilot story is likely wartime propaganda. However, some controlled studies do show modest improvements in dark adaptation speed with bilberry supplementation. The effect is more pronounced in people with impaired night vision than in healthy individuals with normal vision.

Yes. A 2015 randomized controlled trial in Japanese VDT (screen) workers found that 480 mg of bilberry extract daily significantly reduced subjective eye fatigue and improved accommodative function after 8 weeks compared to placebo. ^[1]

They serve different roles. Lutein has stronger evidence for AMD prevention and macular protection (AREDS2 trial). Bilberry is better studied for eye fatigue and retinal microcirculation. Many eye health supplements combine both for comprehensive support.

Anthocyanins are the primary active compounds, with cyanidin-3-glucoside being the most prominent. These polyphenols protect retinal pigment epithelial cells from oxidative stress and improve capillary blood flow in the retina. Standardized extracts containing 25-36% anthocyanins are recommended for consistent therapeutic effects.

The 2015 Japanese RCT that demonstrated significant eye fatigue reduction used 480 mg of standardized bilberry extract daily. For general eye health support, 160-320 mg daily is commonly used. Split dosing — taking the extract twice daily — may be preferable for sustained blood levels.

Bilberry anthocyanins improve capillary blood flow in the retina, enhancing nutrient delivery to and waste removal from photoreceptors. This microcirculatory support helps maintain the health of the retinal pigment epithelium, a critical cell layer for vision.

Standardized bilberry extract with 25% anthocyanins is the most common and well-studied form. The 36% anthocyanin extract provides higher potency per milligram, which can be useful for achieving therapeutic doses in fewer capsules. Both forms are effective when dosed appropriately.

Bilberry anthocyanins may have mild antiplatelet effects, so they can potentially interact with anticoagulants like warfarin, aspirin, and antiplatelet drugs. People taking blood-thinning medications should consult their healthcare provider before supplementing with bilberry, particularly at high doses.

Bilberry may modestly lower blood sugar, which is a concern for people taking diabetes medications. This effect could cause an additive blood sugar reduction when combined with insulin or oral hypoglycemic drugs. Those on diabetes medications should monitor blood glucose closely if supplementing with bilberry.

Standardized bilberry extract concentrates the active anthocyanins to 25-36%, providing consistent therapeutic doses. Whole bilberry powder has a lower anthocyanin concentration but includes additional fiber and whole-food compounds. For targeted eye health support, the standardized extract delivers more active compound per serving.

A 2012 systematic review identified 30 clinical trials on bilberry and eye health. Earlier studies were methodologically weak, but newer RCTs — including the 2015 trial with 88 VDT workers — show clear benefits for eye fatigue and retinal microcirculation. The evidence level is classified as moderate overall.

Bilberry can be safely combined with lutein and zeaxanthin. They work through different mechanisms — lutein and zeaxanthin filter blue light and build macular pigment, while bilberry anthocyanins support retinal microcirculation and reduce eye fatigue. Many comprehensive eye health formulas include all three.

Bilberry extract is generally safe for long-term use at recommended doses of 160-480 mg daily. Side effects are mild and infrequent, primarily limited to gastrointestinal upset. Doses above 600 mg per day have not been well studied, so staying within the established dosage range is advisable.

Bilberry has emerging evidence for retinal support at doses of 320-480 mg daily, primarily through its role in improving microcirculation and providing antioxidant protection to retinal pigment epithelial cells. However, the evidence for specific retinal disorders is less robust than for eye fatigue and is classified as emerging.